Search

Your search keyword '"Fujimaki, Katsumichi"' showing total 479 results

Search Constraints

Start Over You searched for: Author "Fujimaki, Katsumichi" Remove constraint Author: "Fujimaki, Katsumichi"
479 results on '"Fujimaki, Katsumichi"'

Search Results

2. Comparison of standardized prophylactic high-dose and intrathecal methotrexate for DLBCL with a high risk of CNS relapse

3. Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11)

4. Real-world data of AML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11)

5. Importance of TKI treatment duration in treatment-free remission of chronic myeloid leukemia: results of the D-FREE study

6. Nilotinib vs dasatinib in achieving MR4.5 for de novo chronic myeloid leukemia: the randomized JALSG CML212 study

8. Pretransplantation Inflammatory and Nutritional Status in Elderly Allogeneic Hematopoietic Stem Cell Transplantation: Prognostic Value of C-Reactive Protein-to-Albumin Ratio

9. Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial

10. Long‐term treatment with fostamatinib in Japanese patients with primary immune thrombocytopenia: An open‐label extension study following a phase 3 placebo‐controlled, double‐blind, parallel‐group study

12. Comparison of Clinical Features Between Primary and Secondary Breast Diffuse Large B Cell Lymphoma: A Yokohama Cooperative Study Group for Hematology Multicenter Retrospective Study

13. Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11)

14. Real-world data of AML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11)

15. MO49-1 The efficacy of high-dose versus intrathecal methotrexate for DLBCL with high risk of CNS relapse: A multicenter retrospective study

16. Prognostic significance of the CFA ratio for newly diagnosed acute myeloid leukemia: A multicenter retrospective study.

17. Efficient detection of somatic UBA1 variants and clinical scoring system predicting patients with variants in VEXAS syndrome

18. Clinical Significance of Serum Ferritin at Diagnosis in Patients With Acute Myeloid Leukemia: A YACHT Multicenter Retrospective Study

19. Impact of treatment-related weight changes from diagnosis to hematopoietic stem-cell transplantation on clinical outcome of acute myeloid leukemia

20. Tamibarotene maintenance improved relapse-free survival of acute promyelocytic leukemia: a final result of prospective, randomized, JALSG-APL204 study

22. Beta-2 microglobulin is a strong prognostic factor in patients with DLBCL receiving R-CHOP therapy

23. R-CHOP therapy alone for limited-stage follicular lymphoma

24. Analysis of outcomes in patients with supra-diaphragmatic vs infra-diaphragmatic diffuse large B cell lymphoma treated with R-CHOP therapy

25. Fostamatinib for the Treatment of Japanese Patients with Primary Immune Thrombocytopenia: A Phase 3, Placebo-Controlled, Double-Blind, Parallel-Group Study

26. The Efficacy of High-Dose Versus Intrathecal Methotrexate for Diffuse Large B-Cell Lymphoma with High Risk of CNS Relapse: A Multicenter Retrospective Study with Uniform CNS Prophylaxis

28. Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study

29. Body mass index is a prognostic factor in adult patients with acute myeloid leukemia

30. Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol

31. Absolute monocyte count in follicular lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone

32. Clinical significance of the administration of cytarabine or thiotepa in addition to total body irradiation and cyclophosphamide for allogeneic hematopoietic cell transplantation in patients with acute leukemia

34. Fostamatinib for the treatment of Japanese patients with primary immune thrombocytopenia: A phase 3, placebo‐controlled, double‐blind, parallel‐group study.

35. Clinical significance of minimal residual disease detected by multidimensional flow cytometry: Serial monitoring after allogeneic stem cell transplantation for acute leukemia

36. Evaluation of soluble interleukin-2 receptor and serum lactate dehydrogenase in malignant lymphoma

37. Importance of the Duration of TKI Treatment in Treatment-Free Remission of Chronic Phase Chronic Myeloid Leukemia: Results of D-Free Trial

38. Very Low-Dose Dasatinib Is a Safe and Effective Therapy for Elderly Patients with Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results from the Davlec Study, a Single-Arm, Multicenter, Phase 2 Trial

40. Prognostic significance of serum beta-2 microglobulin level in Hodgkin lymphoma treated with ABVD-based therapy

42. Successful treatment with lenalidomide for relapsed adult T-cell leukemia/lymphoma after cord blood cell transplantation

46. Incidence, risk factors and outcomes of bronchiolitis obliterans after allogeneic stem cell transplantation

48. Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large B-cell lymphoma in the rituximab era

49. European Treatment and Outcome Study score does not predict imatinib treatment response and outcome in chronic myeloid leukemia patients

50. Passenger lymphocyte syndrome after ABO-incompatible allogeneic hematopoietic stem cell transplantation; dynamics of ABO allo-antibody and blood type conversion

Catalog

Books, media, physical & digital resources